Negative association between erythrocyte reduced glutathione concentration and diabetic complications

Clinical Science

Volumn 91, Issue 5, 1996, Pages 575-582

  Thornalley, P J ^a,b   McLellan, A C ^a   Lo, T W C ^b   Benn, J ^a   Sonksen P H ^a  

^a UNIVERSITY OF ESSEX   (United Kingdom)

^b ST THOMAS HOSPITAL   (United Kingdom)

Author keywords

Diabetes mellitus; Glyoxal; Glyoxalase; Methylglyoxal; Oxidative stress

Indexed keywords

GLUTATHIONE; GLUTATHIONE REDUCTASE; GLYCOSYLATED HEMOGLOBIN; LACTOYLGLUTATHIONE LYASE; METHYLGLYOXAL;

ADULT; AGE; AGED; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DIABETIC NEUROPATHY; DIABETIC RETINOPATHY; DISEASE DURATION; ENZYME ACTIVITY; ERYTHROCYTE; FEMALE; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR CLINICAL STUDY; MALE; OXIDATIVE STRESS; PRIORITY JOURNAL; REGRESSION ANALYSIS;

EID: 0029912862     PISSN: 01435221     EISSN: None     Source Type: Journal    
DOI: 10.1042/cs0910575     Document Type: Article

References (39)

1. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 327:977-86.
2. Turner RC, Holman RR. Lessons from the UK prospective diabetes study. Diabetes Res Clin Pract 1995; 28: S151 -7.
3. Raskin P. Risk-factors for the development of Diabetic complications. J Diabetes Complications 1995; 8:195-200.
4. Brownlee M, Cerami A, Vlassara H. Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications. N Engl J Med 1988; 318:1315-21.
5. Baynes JW. Role of oxidative stress in development of complications in diabetes. Diabetes 1991 MO: 405-12.
6. Murakami K, Kondo T. Ohtsuka Y, Fujiwara Y, Shimada M, Kawakami Y. Impairment of glutathione metabolism in erythrocytes from patients with diabetes mellitus. Metabolism 1989; 38:753-8.
7. McCance DR. Dyer DG, Dünn JA, et al. Maillard reaction products and their relation to complications in insulin-dependent diabetes mellitus. J Clin Invest 1993; 91:2470-8.
8. Thomalley PJ. Methylglyoxal, glyoxalases and the development of diabetic complications. Amino Adds 1994; 6: 15-23.
9. McLellan AC. Thomalley PJ, Benn J, Sonksen PH. The gryoxalase system in clinical diabetes mellitus and correlation with diabetic complications. Clin Sa 1994; 87:21-9.
10. Thomalley PJ. The glyoxalase system in health and disease. Mol Aspects Med 1993:14:287-371.
11. Lo TWC, Westwood ME. McLellan AC Selwood T. Thomalley PJ. Binding and modification of proteins by methylglyoxal under physiological conditions. A kinetic and mechanistic study with Nracetylarginine, Nacetylcysteine and Nracetyl-lysine, and bovine serum albumin. J Biol Chem 1994; 269: 32299-305.
12. Phillips SA, Thomalley PJ. The formation of methylglyoxal from triose phosphates. Investigation using a specific assay for methylglyoxal. Eur J Biochem 1993:212:101-5.
13. Pompliano DU Peyman A, Knowies JR. Stabilization of a reaction intermediate as a catalytic device: definition of the functional role of the flexible loop in triosephosphate isomerase. Biochemistry 1990; 29:3186-94.
14. Koop DR, Casazza JP. Identification of ethanol-indudble P-450 isozyme 3a as the acetone and acetol monooxygenase of rabbit mkrosomes. J Biol Chem 1985; 260: 13607-612.
15. Lyles GA, Chalmers J. The metabolism of aminoacetone to methylglyoxal by semicarbazide-sensitive amino oxidase in human umbilical artery. Biochem Pharmacoll992;:l409-l4.
16. Smith PR, Thomalley PJ. Mechanism of the degradation of fructosamines under physiological conditions. Studies with the model pepu'de fructosamine Nrl-deoxy-D-fructos-l-yl-hippuryl-lysine. Eur J Biochem 1992; 210: 729-39.
17. Wells-Knecht K), Zyzak DV, LichfieM JE, Thorpe SR, Baynes JW. Mechanism of autoxidative glycosylation: identification of glyoxal and arabinose as intermediates in the autoxidative modification of proteins by glucose. J Am Chem Soc 1995; 34: 3702-9.
18. Loidl-Stahlhofen A, Spitefler G. i-Oxoaldehydes, products of lipid peroxidation. BiochimBiophysActa 1994; 1211: 156-60.
19. Glomb MA, Monnier VM. Mechanism of protein modification by glyoxal and glycolaldehyde, reactive intermediates of the Maillard reaction. J Biol Chem 1995; 276:10017-25.
20. McLellan AC, Phillips SA, ThomaHey Pj. The assay of methylglyoxal in biological systems by derivatization with l,2-diamino-4,5-dimethoxvbenzene. Anal Biochem 1992; 206: 17-23.
21. Pirart J. Diabetes mellitus and its degenerative complications: a prospective study of 4,400 patients observed between 1947 and 1973. Diabetes Care 1978; I: 168-88.
22. Knuiman MW, Welboum TA. McCann V|, Stanton KG, Constable IJ. Prevalence of diabetic complications in relation to risk factors. Diabetes 1986; 35: 1332-9.
23. The DCCT Research Group. Factors in the development of diabetic neuropathy: baseline analysis of neuropathy in feasibility phase of diabetes control and complications trial (DCCT) Diabetes 1988; 37:476-81.
24. Maser RE, Steenkiste AR, Dorman JS, et al. Epidemiological correlates of diabetic neuropathy. Diabetes 1989; 38:1456-61.
25. Kullberg CE, Arnquist HJ. Elevated long-term glycated hemoglobin precedes proliferate retinopathy and nephropathy in type I (insulin-dependent) diabetic patients. Diabetotegia 1993; 36:961 -5.
26. Lui QZ, Pettitt DJ, Hanson Rl_ et al. Glycated hemoglobin, plasma glucose and diabetic retinopathy. cross-sectional and prospective analyses. Diabetologia 1993; 36:428-32.
27. Phillips SA, Mirrlees D, Thomalley PJ. Modification of the glyoxalase system in streptozotocin-induced diabetic rats. Effect of the aldose reductase inhibitor Statil. Biochem Pharmacol 1993; 46:805-811.
28. Shinohara M, Giardino I, Brownlee M. Overexpfession of glyoxalase I inhibits intracellular advanced glycation endproduct (AGE) formation. Diabetes 1996; 45 (Suppl. 2): I26A.
29. Papoulis A, AI-Abed Y, Bucala R. Identification of N2-( I -carboxyethyl)guanine (CEG) as a guanine advanced glycosylation endproduct Biochemistry 1995; 34: 648-55.
30. Kang Y, Edwards LG, Thomalley PJ. Effect of methylglyoxal on cell growth: induction of apoptosis in human leukaemia 60 cells but not in concanavalin A-stimulated peripheral human lymphocytes. Leuk Res 1996; 20:397-406.
31. Westwood ME, McLellan AC, Thomalley PJ. Receptor-mediated endocytic uptake of methylglyoxal-modified protein. Competition with advanced gfycation endproduct-modified protein at the advanced glycation endproduct receptor. J Biol Chem 1994; 269:32293-8.
32. Westwood ME, Thomalley PJ. Cytokine synthesis and secretion induced by methylglyoxal-modified proteins. Diabetic Med 1995; 12 (Suppl. 2-10): S49.
33. Abordo E, Argirov OK, Thomalley PJ. Human serum albumin minimally-modified by methylglyoxal but not by glucose-derived advanced glycation endproducts induced the synthesis and secretion of tumour necrosis factor-j (TNFa) by human monocytic THP-I cells in vitro. Diabetes 1996; 45: I29A.
34. Ueno H, Segawa T, Hasegawa T, et al. Subchronic oral toxicity of glyoxal via drinking water in rats. Fundamental Appl Toxicol 1991 ; 16:763 -72.
35. Yan SD, Schmidt AM, Andersen GM, et al. Enhanced cellular oxidant stress by the interaction of advanced glycation end products with their receptors/binding proteins. J Biol Chem 1994; 269:9889-97.
36. Costagliola C. Oxidative state of glutathione in red blood cells and plasma of diabetic patients: in vitro and in vivo study. Clin Physiol Biochem 1990; 8:204-10.
37. Sinclair AJ, Girling AJ, Gray L, Lunée J. Bamett AH. An investigation of the relationship between free radical activity and vitamin C metabolism in elderly diabetic subjects with retinopathy. Gerontology 1992; 38:268-74.
38. Bono A. Caimi A, Catania A, Sarno A, Pandolfo I. Red cell peroxide metabolism in diabetes mellitus. Horm Metab Res 1987; 19:264-6.
39. Jain SK, McVie R. Effect of glycaemfc control, race (white versus black), and duration of diabetes on reduced glutathione content in erythrocytes of diabetic patients. Metabolism 1994; 43:306-9.